Speaker Details

Iltefat H. Hamzavi, MD, FAAD

Iltefat H. Hamzavi, MD, FAAD

SESSIONS

S006 Vitiligo
Mar 7, 2025 • 9:00 AM - 12:00 PM • W308A
U097 In Office Surgical Techniques for the Treatment of Moderate to Severe Hidradenitis Suppurativa (HS)
Mar 10, 2025 • 7:30 AM - 8:30 AM • W207A

HANDOUTS

Login to view handouts

DISCLOSURES

AbbVie – Advisory Board(Fees); Almirall – Consultant (1099 relationship)(Fees); Avita – Investigator(Grants/Research Funding); Beiersdorf, Inc. – Advisory Board(Fees); Boehringer Ingelheim – Consultant(Fees); Clinuvel – Investigator(Fees); Galderma Laboratories, L.P. – Investigator(Fees); Global Vitiligo Foundation – Board of Directors(No Compensation Received); Hidradenitis Suppurativa Foundation – Board of Directors(No Compensation Received); Incyte Corporation – Investigator(Grants/Research Funding); Janssen Biotech – Investigator(Grants/Research Funding); L'Oreal USA Inc. – Investigator(Grants/Research Funding); Lenicura – Investigator(Equipment); MyDerm Portal, Inc – Stockholder(Stock); Novartis – Consultant(Fees); Pfizer Inc. – Investigator(Fees); Sonoma Biotherapeutics – Investigator(Grants/Research Funding); Teva Pharmaceutical Industries Ltd. – Investigator(Fees); UCB – Consultant(Fees); Union Therapeutics – Consultant(Fees); Vimela – Consultant (1099 relationship)(Fees);